Ferric Carboxymaltose: Ironing Out the Issues Around Heart Failure Related Readmissions

This webinar is the first in a series of six webinars from the ISCP focusing on the A to Z of CV Pharmacotherapy.

Future webinars in this series include:

For more details of upcoming webinars please visit our upcoming events section.

Do you know when, how and on which patients to use ferric carboxymaltose to treat heart failure?

Iron deficiency can have a negative impact on both mitochondrial and cardiac function and on the structure of the heart, this can lead to heart failure. Ferric carboxymaltose can improve both cardiac structure and performance.

Led by moderators Chan Hong (Singapore) and Franco Cheng (Hong Kong), it includes a speaker presentation from David Sim (Singapore) and a discussion from panellists Maurizio Volterrani (Italy) and Daniel Lighezan (Romania) that will examine the importance of ferric carboxymaltose, through consideration of real-world examples, live discussions and audience Q&A.

To evaluate and understand the importance of iron in Heart Failure
To evaluate and understand when and how to use ferric carboxymaltose in Heart Failure
To apply evidence-based recommendations to two real world cases